Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Investor Presentation (July 2018)
24 slides from Anatara Lifesciences's investor presentation, Jul 18, 2018
Slide 1: Investor presentation and strategy update
ASX Release Investor presentation and strategy update BRISBANE, 18th July 2018: Anatara Lifesciences (ASX:ANR) is pleased to release its latest presentation and strategy update that will be delivered to institutional investors this week. In outlining its future strategy, Anatara has provided an upda
Slide 2: From animals to humans
From animals to humans July 2018 Dr Jay Hetzel, Chairman Dr Tracie Ramsdale, CEO Dr Tracey Brown, CDO Anatara Lifesciences (ASX:ANR)
Slide 3: Disclaimer
Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company).
Slide 4: Anatara Corporate History
Anatara Corporate History Zoetis Option Expand Management Team Melbourne lab established Target animal safety (TAS) Global License ASX Listing study complete with Zoetis for First commercial Submit Detach Detach for scale up of Detach dossier to livestock and manufacture APVMA horses 2014 2016 2018
Slide 5: Presentation Highlights
Presentation Highlights • Signed exclusive global agreement with Zoetis for the worldwide development, manufacturing, distribution and marketing of Detach in livestock and horses • Human gastrointestinal program reviewed and refined, resulting in strong initial candidate for restoring and maintainin
Slide 6: Animal Health
Animal Health • A natural, safe, non-antibiotic product that aids in the control of diarrhea (known as scour) in livestock • Anatara has signed an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacturing, distribution, and
Slide 7: From animals to humans
From animals to humans
Slide 8: Anatara’s Technology
Anatara’s Technology • Bromelain is a natural product extracted from pineapple stems. • Based on decades of research by world- class academic and commercial partners which found that bromelain contains a number of proteases with distinct biological activities, including • Anti-attachment • Anti-secr
Slide 9: Human strategy – strategic review
Human strategy – strategic review • Potential applications for Anatara’s technology exist in • childhood diarrhea • traveller’s diarrhea • diarrhea associated with gastrointestinal disorders such as IBD and IBS • Following a thorough review of each of these opportunities, the IBD/IBS indication was
Slide 10: About Inflammatory Bowel Disease (IBD)
About Inflammatory Bowel Disease (IBD) • Two forms: Ulcerative Colitis and Crohn’s Disease • Patients experience abdominal pain and cramping, bloating, blood and mucus in the stool, loss of appetite and persistent diarrhea >5m • Treatment involves suppressing IBD sufferers inflammation with the goal
Slide 11: About Irritable Bowel Syndrome (IBS)
About Irritable Bowel Syndrome (IBS) • IBS is a functional disorder. Incomplete knowledge of pathology, therefore the approach is symptom management • Symptoms include abdominal pain, bloating and alternating constipation and diarrhea • Patients have a poor quality of life and utilise the healthcare
Slide 12: Anatara has designed a novel product aimed at restoring and maintaining gut health
Anatara has designed a novel product aimed at restoring and maintaining gut health: Gastrointestinal Reprogramming Product (GaRP) For the Management of Gastrointestinal Disorders 11
Slide 13: Target Gastrointestinal Disorders
Target Gastrointestinal Disorders Irritable Bowel Inflammatory Bowel Syndrome (IBS) Disease (IBD) Low grade inflammation Chronic inflammation Shared disease characteristics: Altered microbiome Impaired intestinal barrier function Mucosal damage IBS and IBD are areas of significantly unmet clinical n
Slide 14: The Microbiome and IBD/IBS
The Microbiome and IBD/IBS Healthy gut microbiome • Supplies energy and nutrients • Immune system development • Defence against pathogens Healthy gut – increased diversity IBD/IBS gut microbiome • Less bacteria with anti-inflammatory properties • More bacteria with pro-inflammatory properties • Redu
Slide 15: How GaRP works?
How GaRP works? GaRPwill GaRP is abemicrobiome-targeted dietary supplement a microbiome-centric complementary medicine*aimed at: aimed at: Correcting gut Alleviation of Repair of gut microbiota the Reduction of lining and to restore symptomatic inflammation, barrier normal diarrhea leading to defect
Slide 16: Dietary Supplements as an adjunct to prescription drugs for the treatment of GI disorders
Dietary Supplements as an adjunct to prescription drugs for the treatment of GI disorders • GI disorders affect a significant proportion of the population. • ~50% of patients seek additional relief of their symptoms through adjunct therapies • Increased education and more detailed evaluation of diet
Slide 17: GaRP – built on strong scientific foundations
GaRP – built on strong scientific foundations 16
Slide 18: About bromelain
About bromelain Generally Recognised Unlimited Acceptable But formal clinical as Safe (GRAS) Daily Intake (ADI) data has been lacking Bromelain is allowed in food as a Bromelain has been used for A lot of anecdotal evidence food additive and it has been decades in as an anti-inflammatory regarding i
Slide 19: Dual targeted product combining bromelain and other GRAS components
Dual targeted product combining bromelain and other GRAS components* Ileum targeted components • prevent attachment of pro-inflammatory bacteria • restore gut microbiota • reduce inflammation Ileum Colon targeted components • restore gut microbiota • reduce inflammation • mucosa regeneration • resto
Slide 20: GaRP Development Plan – next steps
GaRP Development Plan– next steps • Proof of concept studies are well advanced to demonstrate that GaRP can: • Remove bacteria with pro-inflammatory properties • Reduce inflammation by reducing the release of proinflammatory cytokines • Reduce serotonin-induced diarrhea (important for IBS) • Regener
Slide 21: Regulatory advantages of dietary supplements
Regulatory advantages of dietary supplements* The advantages of a dietary supplement regulatory strategy are: 1. Less expensive and less risky pathway to market 2. Rapid market entry 3. Public and healthcare professionals understand the term ‘dietary supplement’ 4. Marketing can be aimed at both the
Slide 22: A clear path to commercialisation
A clear path to commercialisation 2017 2017 2018 2018 2019 2019 2020 2020 H1 H2 H1 H2 H1 H2 H1 H2 Confirmed GRAS status for components with FDA Established collaboration with University of Liverpool (UK) Completed product development plan Patent Application filed Commercial feasibility M
Slide 23: Investment Summary
Investment Summary • GaRP a large addressable and growing market and rapid development path • Anatara has the funds necessary to progress GaRP through to a partnering deal in 2020 • Anatara has initiated discussions with sector specialists to maximise the commercial potential of a GaRP partnering de
Slide 24: Thank you
Thank you Dr Jay Hetzel, Chairman jhetzel@anatara.com Dr Tracie Ramsdale, CEO & Director tramsdale@anatara.com Dr Tracey Brown, Chief Development Officer tbrown@anatara.com www.anataralifesciences.com @AnataraANR 23
Anatara Lifesciences — Investor Presentation (July 2018) on 6ix